Background/Aims: The voltage-gated potassium channel K V 11.1 has been originally cloned from the brain and is expressed in a variety of tissues. The role of phosphorylation for channel function is a matter of debate. In this study, we aimed to elucidate the extent and role of protein kinase D mediated phosphorylation. Methods: We employed mass spectrometry, whole-cell patch clamp electrophysiology, confocal microscopy, site-directed mutagenesis, and western blotting. Results: Using brain tissue from rat and mouse, we mapped several phosphorylated K V 11.1 residues by LC-MS mass spectrometry and identified protein kinase D (PKD1) as possible regulatory kinase. Co-expression of K V 11.1 with PKD1 reduced current amplitudes without altering protein levels or surface expression of the channel. Based on LC-MS results from in vivo and HEK293 cell experiments we chose four K V 11.1 mutant candidates for further functional analysis. Ablation of the putative PKD phosphorylation site in the mutant S284A increased the maximal current indicating S284 as a main PKD target in K V 11.1. Conclusions: Our data might help mitigating a long-standing controversy in the field regarding PKC regulation of K V 11.1. We propose that PKD1 mediates the PKC effects on K V 11.1 and we found that PKD targets S284 in the N-terminus of the channel.
Introduction
The potassium channel K V 11.1 is encoded by KCNH2 and also known as human-ethera-go-go related gene type 1 (hERG of tissues including brain, heart, pancreas, vasculature, and a number of tumors [1] . It is best known for its role in the heart, where it is the molecular correlate of the rapid delayed rectifying current I Kr [2, 3] . Mutations in the KCNH2 gene are associated with several cardiac arrhythmias such as Long QT and Short QT syndromes and atrial fibrillation [1, 2, 4] . Several posttranscriptional and posttranslational mechanisms have been described to finetune expression levels and/or biophysical parameters of K V 11.1 [5] [6] [7] . Protein kinase A (PKA) phosphorylates K V 11.1 directly at four consensus sites in vitro [8, 9] . Protein kinase C (PKC) effects have been investigated in different expression systems and experimental models (reviewed in [1] ). Despite numerous studies, it is still unresolved whether PKC directly phosphorylates the channel protein. Identification of 18 consensus sites by prediction algorithms and individual ablation of these sites did not provide any evidence for a direct phosphorylation at these sites [10, 11] . Cockerill et al. provided evidence for a role of the channel's N-terminus for PKC mediated phosphorylation [11] . It has been suggested that an atypical PKC phosphorylation site might be involved in the PKC effects [1, 11] .
Noteworthy, multiple lines of evidence indicate that PKC activity is indispensable for activation of protein kinase D (PKD). Especially, the novel PKCs Ɛ and h give robust activation of PKD [12] but also classical PKCα can activate PKD [13] . PKD is expressed in a variety of tissues and its function has been implicated in health and disease (reviewed in [14] [15] [16] ). Several studies found that a variety of stimuli induce PKD activation through the α-adrenergic pathway, and in many cases this could be attenuated by PKC inhibition [17] [18] [19] . Here, we hypothesized that PKC effects on K V 11.1 are mediated through PKD1.
Materials and Methods
Protein biochemistry Preparation of brain samples. All procedures involving animals conformed to Danish animal welfare regulations. Briefly, mouse or rat brain was cut in smaller pieces, homogenized in buffer [in mM: 50 Tris/HCl pH 7.4, 2.5 EGTA, 5 EDTA, 10 NaCl, 10 KCl, 0.5 pefabloc, 0.1 NaF, and 320 sucrose with a protease inhibitor cocktail (in µg/mL: 2 aprotinin, 1 leupeptin, 2 antipain, 10 benzamidine, and one tablet of phosSTOP/10 mL)] and centrifuged. The supernatant was retained, centrifuged again, and pellets were resuspendend in 2.5 mL homogenizing buffer for every gram of brain.
Preparation of HEK293 cell samples. HEK293 cells were transfected with K V 11.1 alone or co-expressed with PKD1. For mass spectrometry the cells were grown in a special media, immunoprecipitated and digested to peptides. For lysates cells were harvested in solubilization buffer without detergent [in mM: 50 Tris pH 8.5, 150 NaCl, 5 EDTA] and supplemented with 8 µM leupeptin, 0.4 mM pefabloc and one tablet of phosSTOP pr. 10 mL, centrifuged (2 min, 100 x g) and incubated with solubilization buffer containing 1% NP-40 on a spinning wheel for 3 hours. Samples were centrifuged at >10.000 x g for 10 min and supernatants were aliquoted, frozen in liquid nitrogen and stored until further use.
Sample preparation for mass spectrometry. Sample lysates were precleared with Protein G-dynabeads (Invitrogen). Then primary antibody (2 μg/1 mg total protein in the sample) was added followed by overnight incubation. After addition of dynabeads in lysis buffer [in mM: 50 Tris/HCl, pH 8.5, 5 EDTA, 150 NaCl] containing 1% NP-40, 8 µM leupeptin (Sigma), 0.4 mM pefabloc (Sigma), one tablet of phosSTOP pr. 10 mL (Roche) and incubation for 2 h, multiple wash steps were performed. At the end beads were resuspended in Laemmli buffer (containing 100 mM DTT) and incubated for 3 min at 70°C.
Mass spectrometry. Immunoprecipitated proteins were separated by SDS-PAGE, fixed, stained, bands excised and proteins proteolytically cleaved to peptides as previously described [20, 21] . Peptide separation was performed by reversed-phase C 18 HPLC on an Easy nLC system (Thermo Fisher Scientific). The effluent from the HPLC was directly electrosprayed into an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Slangerup, Denmark) through a nano-spray ion source. The peptide mixture was analyzed by full-scan MS spectra (m/z 300-2000, resolution 30, 000) in the Orbitrap analyzer. For every full-scan the 
Patch-clamp electrophysiology
Recordings. All recordings of transiently transfected HEK293 cells were performed in the whole-cell patch clamp configuration using an EPC9 patch clamp amplifier (HEKA Elektronik, Lambrecht, Germany). Data acquisition was done with the Pulse software (HEKA Electronik). The series resistance recorded in the whole cell configuration was kept below 10 MΩ and compensated ( Data analysis. Data analysis was performed using Excel (Microsoft), Igor Pro 4.04 (Wavemetrics, OR, USA) and Prism 4 (GraphPad Software, CA, USA). All values are given as mean ± SEM. The number of independent experiments is indicated by n. Statistical comparisons of results were performed using oneway analysis of variance (ANOVA) or two-way ANOVA. Following ANOVA, Bonferroni's method of multiple comparisons was used to identify significant differences between means. A value of P <0.05 was considered statistically significant.
Antibodies
Primary antibodies: anti-K V 11.1, APC-062 (Alomone, Jerusalem, Israel, 1:500); anti-PKD1, H00005587-A01 (Abnova, Roskilde, Denmark, 1:500); anti-β-tubulin, MAB3408 (Millipore, Hellerup, Denmark, 1:4000).
Secondary antibodies: For western blot analyses; peroxidase conjugated affinipure F(ab)fragment donkey anti-rabbit and anti-mouse (Jackson ImmunoResearch, Suffolk, UK), donkey anti-mouse 680RD, 926-68072 (LI-COR Biosciences, Copenhagen, Denmark); goat anti-rabbit 800CW, 926-32211 (LI-COR Biosciences). For confocal imaging; Alexa Fluor®488-conjugated donkey anti-rabbit IgG (1:200), Alexa Fluor®568-conjugated donkey anti-mouse IgG (1:200). Alexa®Fluor 647 Phalloidin (1:200) was used to stain actin filaments and DAPI (1:300) was used to stain the nucleus. Secondary antibodies were purchased from Invitrogen (Glostrup, Denmark).
Molecular biology
Point mutations in K V 11.1 (GenBank Acc. No. NM_000238) were introduced by standard site-directed mutagenesis. All constructs were verified by complete DNA sequencing of the cDNA insert (Macrogen Inc., Seoul, Rep. of Korea). Human protein kinase D1 (PKD1, NM_002742) expression plasmid was kindly provided by Dr. A. Hausser (University of Stuttgart, Germany) [22] .
Results

K V 11.1 is phosphorylated in vivo at a residue matching a consensus recognition site for PKD
First, we mapped the in vivo phosphorylation sites of K V 11.1 using tissue samples, where K V 11.1 channels from both mouse and rat brain tissue were purified by immunoprecipitations and submitted to analysis by LC-MS/MS mass spectrometry. Our analysis led to identification of 14 in-vivo phosphorylation sites (Table 1 ). In Table 1 we assigned the identified residues
from mouse and rat to the nomenclature of the human K V 11.1 residues by alignment of mouse, rat, and human sequences (see online suppl. material, Suppl. Fig. S1 ). Our data confirmed phosphorylation at residue S283 which had been reported as a site for PKA-mediated phosphorylation previously [9] . None of the identified residues were PKC consensus sites; however, S284 was a strong candidate for PKD phosphorylation.
Co-expression of PKD1 reduces K V 11.1 current densities
We assessed a possible role of PKD1 by employing whole-cell patch clamp recordings. We transiently transfected HEK293 cells with K V 11.1 alone or coexpressed with PKD1 cDNA (Fig. 1) . To investigate the potassium currents, we applied a standard step protocol with 1 s test pulses ranging from -100 to +60 mV in 10 mV increments. Fig. 1A shows representative current recordings of K V 11.1 and K V 11.1 + PKD1. As expected, the current/voltage relationship (IV curve) resulted in the characteristic bell-shape due to inactivation of the channel [3] . Of note, a high degree of cell to cell variability of current levels was seen in line with literature [23] . The maximum outward current amplitude was normalized to the cell capacitance and used to construct the current-voltage (I-V) relationship of K V 11.1 (n=7) and K V 11.1 co-expressed with PKD1 (n=7) (Fig. 1B) . The maximum outward current amplitude at +20 mV for K V 11.1 was 29.5±9.5 pA/pF and significantly reduced by 56.2 % upon co-expression with PKD1 (12.9±1.7 pA/pF, P=0.018). The tail current amplitude was also reduced by PKD1 co-expression (Fig. 1C) . K V 11.1 current reduction has earlier been assigned to a shift of the voltage-dependent activation to more depolarized potentials [24] . Therefore, the normalized peak tail currents were fitted to a Boltzmann function to determine the V ½ values of voltage-dependent activation. No difference of the voltage-dependent activation upon co-expression of PKD1 (Fig. 1D , Table 2 ) was observed. Deactivation, inactivation and recovery from inactivation properties ( Table  2) were unchanged.
PKD1 co-expression does not alter protein levels or surface expression of Kv11.1
We assessed whether PKD1 co-expression would affect K V 11.1 protein expression or subcellular localization. Western blot experiments revealed that there was no change in protein levels (see online suppl. material, Suppl. Fig. S2 ). PKD1 did not alter the localization of K V 11.1 in HEK293 cells, and K V 11.1 and PKD1 were both localized in the plasma membrane as assessed by confocal microscopy (see online suppl. material, Suppl. Fig. S3 ). Attempts to test a possible direct interaction between K V 11.1 channel and PKD1 by co-immunoprecipitation remained unsuccessful (data not shown).
PKD1 co-expression leads to K V 11.1 phosphorylation in HEK293 cells
To analyse whether S284 and other residues would be phosphorylated by PKD1, we immunoprecipitated K V 11.1 channels co-expressed with PKD1 in HEK293 cells to map the phosphorylation sites by mass spectrometry. We identified seven residues that were phosphorylated upon co-expression with PKD1. This indicated that PKD1 could affect K V 11.1 phosphorylation in a heterologous expression system by direct phosphorylation of several residues. MS/MS spectra for all identified sites with evidence for site localization are provided (see online suppl. material) in Suppl. Fig. S4-9 . A few residues did stand out from the data; Residue S284 appeared to be phosphorylated in HEK293 cells co-expressed with PKD1. In addition, it was identified in vivo and motif-wise PKD1 was the most likely kinase to phosphorylate this site, making S284 our prime candidate for PKD1 phosphorylation. Also amino acids S263 and S266 were phosphorylated. S266 was identified to be phosphorylated by itself, whereas S263 was only identified in peptides where S266 was also phosphorylated and we decided to address their combined effect in the subsequent functional analysis. S322 was phosphorylated and found in a cluster together with S318, T319, and S320. Three of the four were found phosphorylated in vivo. We chose to address the combined effects of the four residues in the cluster. Finally, residue T353 appeared to be phosphorylated in HEK293 cells and in vivo.
Functional analysis of K V 11.1 mutants supports S284 as possible PKD target
We sought to address the functional impact of the selected amino acids after ablation of the serine residues to alanine (A) hereby mimicking the dephosphorylated state. To this end, we generated four K V 11.1 mutants (K V 11.1-S284A, K V 11.1-S263/S266A, K V 11.1-S318/ 
T319/S320/S322A, and K V 11.1-T353A). We expressed the mutant channels in HEK293 and analysed biophysical parameters by patch-clamp electrophysiology. K V 11.1-S284A displayed a significantly higher maximum outward current amplitude than wild-type K V 11.1 at +20 mV; S284A: 58.2±6.9 (n=11), WT: 29.9±3.5 pA/ pF (n=8, P<0.001) respectively; ( Fig. 2A,B) indicating that this residue mediates at least some of the PKD1 phosphorylation effect on the channel. Also the tail current amplitude was significantly higher for the mutant (Fig.  2C) . We did not observe any significant shift in the voltage-dependent activation for K V 11.1-S284A compared with wild-type (Fig. 2D, Table 3 ). The slow time constant of deactivation was significantly faster at -60 and -50 mV for the S284A mutant compared to wild-type. Other voltage-dependent and kinetic parameters were unaffected by the alanine mutation (Table 3) . We analysed protein levels of S284A by western blotting experiments and found that expression levels were similar to wild-type channels (see online suppl. material, Suppl. Fig. S2 ). K V 11.1-S263/S266A, K V 11.1-S318/T319/ S320/S322A, and K V 11.1-T353A behaved similarly to wild-type channels (see online suppl. material, Suppl. Table S1 ).
Discussion K V 11.1 is an important potassium channel which is manifested in its association with inherited and acquired cardiac arrhythmia where even mild changes of the conducted current [11, [25] [26] [27] [28] [29] . Hence, understanding the molecular basis of the regulation is crucial for elucidating disease mechanisms [1, 30] . Here, we provide evidence for involvement of protein kinase D based on in vivo and in vitro mass-spectrometry findings together with functional analysis of wild-type and mutant K V 11.1 channels. LC-MS mass spectrometry revealed several phosphorylated residues in vivo and suggested PKD as a strong candidate. Co-expression of K V 11.1 with PKD1 reduced current amplitudes; however, we were unable to identify significant changes in kinetic parameters that could explain the decrease in I max . Protein levels were unaffected. Due to the lack of specific pharmacological tools, i.e. specific activators or blockers of PKD1 which would allow for an assessment of PKD1 effects independent of PKC in patch-clamp recordings [14] , we instead chose four candidate K V 11.1 mutants for further functional analysis based on the results obtained from HEK293 cell experiments and in vivo data. Ablation of the putative PKD phosphorylation site in the mutant S284A increased the maximal current.
Our data might help mitigating a long-standing controversy in the field regarding PKC regulation of the channel. Most studies have investigated the acute effects of different pathways upstream of PKC activation with variable results ranging from reports indicating that neither PKC nor PKA are involved [31] , that PKA and PKC show composite and partial effects with complex cross-talk [32] , or that either convential PKC (cPKC) [10] or novel PKC (nPKC) [25] are exclusively involved. Other pivotal points of discussion have been whether PKC phosphorylates the channel directly [10, 11, 27] and whether PKC mediated phosphorylation increases [32] or decreases current K V 11.1 (or I Kr ) amplitudes [10, 11, 24, 26, 27] . However, the majority of studies found a positive shift in the voltage-dependence of activation and an acceleration of deactivation, with different levels of reduction of the K V 11.1 current amplitude (e.g [10, 11, 27, 33] .)
Our results support the notion that PKC mediated functional effects are independent of the previously suggested consensus sites [10] . They also confirm a role of the N-terminal part of the protein as proposed by other studies [11, 34] . Cockerill and coworkers found that residues 2-354 of the K V 11.1 N-terminus are critical for both cPKC phosphorylation and functional modulation of the channel [11] . Of note, both cPKC [13] and nPKC [12] have been reported to activate PKD1. While we cannot rule out that PKC exerts a variety of direct and indirect effects, we propose that PKD1 is a new player, either activated independently or downstream of PKC, targeting S284 in the N-terminus of the channel.
Recent attempts to resolve the identity of the involved PKC isoform by using inhibitory peptidomimmetics indicated a predominant role of PKCε, with minor contributions of PKCβ, PKCα, and PKCη [35] . Interestingly, Haworth and coworkers reported that in adult cardiomyocytes PKCε is the predominant activator of PKD and this activation was somewhat counteracted by PKA activation indicating a crosstalk between the two kinase pathways [18] . This crosstalk might mainly be a PKC effect on the cAMP level [36, 37] , but the molecular mechanism behind this is currently unclear. Therefore, we did not investigate the candidates that are already known to be phosphorylated by PKA.
Conclusion
Our data indicate that PKD1 contributes to K V 11.1 regulation by targeting S284 in the N-terminus of the channel. This pathway could therefore present an explanation to years of divergent results regarding the regulation of I Kr or K V 11.1 by protein kinases.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
